MEDVIA offers a warm welcome to seven new members!

• Bio Inx Based in the Tech Lane Ghent Science Park, Bio Inx is a start-up focusing on the development and commercialization of biomaterials for 3D-bioprinting applications. The multidisciplinary team has over 25 years of combined experience in the field of polymers, (bio)materials, 3D printing and tissue engineering. The company has just announced that it has launched a new bio resin enabling printing in the presence of living cells, in partnership with Nanoscribe.
• Endare Focused on digital innovation, Endare provides custom-built software solutions. Located in Ghent’s Ghelamco Arena, the company works to help its clients boost their efficiency, productivity and competitiveness through digital implementations.
• Feops Also in Tech Lane is Feops, which has developed a cardiac imaging system called HEARTguide. Providing an interactive 3D model of a patient’s heart based on CT scans, the platform helps surgeons to determine the size of an implant and allows them to carry out the procedure virtually before performing it on the patient. Feops was involved in project funding earlier this year, and now its membership is official.
• Persomed A consortium founded by myNEO, QbD and Antleron, Persomed has developed a personalized vaccine against colon cancer. The recipient of funding as part of the Flemish government’s Icon project, the group will start a Phase I Trial next year for the Tetramix-DC-NEO vaccine. Lien Lybaert of Persomed discussed in-vivo dendritic cell transfection to treat cancer at the 2022 Science for Health conference in Brussels.
• eTheRNA Based in Niel, Antwerp province, eTheRNA manufactures research-grade RNA. It offers more than 30 years experience in bringing RNA-based research and products from the lab to the clinic.
• MyNeo Focused on the research, development and optimization of personalized cancer immunotherapy, myNEO’s goal is to make identifying neoantigen targets faster and more effective. Based in Ghent, the company’s founding team are accomplished entrepreneurs, continuously investing in new technologies in the biotech industry that have the potential to create a sustainable, long-term impact.
• Pxlence Ghent University spin-off Pxlence provides PCR assays for targeted amplification and sequencing of the human exome. Based in Dendermonde, the company’s main product is an online catalogue of almost one million predesigned PCR assays for targeted resequencing of all canonical exons of human protein coding genes.

MEDVIA memberships are conditional until officially approved by the board of directors